Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

NCT07509112 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER_GOV

Sponsor class

Conditions

Methamphetamine Use Disorder

Interventions

DRUG: 12 weeks of weekly subcutaneous semaglutide injection

Sponsor

Kirby Institute